Array Biopharma, Inc. (ARRY) Posts Q2 Loss of $0.06, Sales Top Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.32 -2.64%
EPS Growth %: -70.0%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
SICP, MNSB, CFFI, More
EPS Growth %: -70.0%
Financial Fact:
General and administrative: 7.86M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- StoneX Reiterates Hold Rating on BOK Financial (BOKF)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
